This fact sheet provides a snapshot of global polio eradication efforts and examines the U.S. government’s role in addressing polio worldwide.
- view as grid
- view as list
This summary of the Coronavirus Aid, Relief, and Economic Security (CARES) Act highlights and summarizes health-related provisions focused on the COVID-19 outbreak in the United States and support for the global response.
A summary of key provisions of the Families First Coronavirus Response Act that addresses the domestic coronavirus outbreak, including paid sick leave, insurance coverage of coronavirus testing, nutrition assistance, and unemployment benefits.
The U.S. government is the largest donor to global health in the world. This fact sheet breaks down the U.S. global health budget by program area: HIV/PEPFAR; tuberculosis (TB); malaria/the President’s Malaria Initiative (PMI); the Global Fund to Fight AIDS, Tuberculosis, and Malaria; maternal & child health (MCH); nutrition; family planning & reproductive health (FP/RH); global health security; and neglected tropical diseases (NTDs).
The U.S. Response to Coronavirus: Summary of the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020, which was passed with near unanimous support in both the House and Senate, was signed into law by the President on March 6, 2020. The bill provides $8.3 billion in emergency funding for federal agencies to respond to the coronavirus outbreak. This summary provides details on funding specified in the bill.
This fact sheet examines the U.S. government’s role in addressing neglected tropical diseases (NTDs) worldwide.
This brief examines the U.S. government’s efforts in global health security – that is, efforts to help countries prepare for and address pandemic and epidemic diseases such Ebola, Zika, and pandemic influenza. The brief provides history and background, reviews the U.S. agencies carrying out these efforts, reviews funding, and highlights key policy issues going forward.
In response to higher drug spending growth and heightened attention to drug prices, policymakers have proposed a variety of policy initiatives to lower the cost of prescription drugs in Medicare. This brief examines in detail the range of proposals offered by the Trump Administration and members of Congress for lowering the cost of prescription drugs, their known effects on the federal budget, and their potential implications for beneficiaries and other stakeholders.
In response to higher drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing Medicare to negotiate the price of prescription drugs. This issue brief provides a short history of this proposal, describes several bills introduced in the 116th Congress to allow government negotiations as well as assessments of potential savings from the Congressional Budget Office (CBO), and considers the prospects for action in the future.